Novartis Presented Results of Remibrutinib (LOU064) in P-IIb Study for the Treatment of Chronic Spontaneous Urticaria at EADV
Shots:
- The P-IIb study evaluates the efficacy & safety of remibrutinib vs PBO in 311 patients with CSU inadequately controlled by H1-antihistamines for 12wks.
- The results showed an improvement in UAS7 related to CFB @4 & 12wks. & rapid improvement as of 1wks.- patients achieved UAS7=0 (complete absence of hives & itch) and UAS7≤6 (well-controlled disease activity)- favorable safety profile & good tolerability across all doses with no dose-dependent pattern. The therapy showed significant dose-response related to CFB in UAS7 score @4wks.
- Remibrutinib is a highly selective- potent BTK inhibitor. The company is expected to start P-III studies of remibrutinib in CSU at the end of 2021
Ref: Novartis | Image: Novartis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com